Review Article
VOLUME: 36 | ISSUE: 2 | Jun 30, 2020 | PAGE: (109 - 117) | DOI: 10.24911/BioMedica/5-123
SPARC in Breast Carcinomas: A Critical Review
Authors: Waqas Arshad Mughal , Sobia Khalid , Nadia Naseem , AH Nagi
Article Info
Authors
Waqas Arshad Mughal
Department of Morbid Anatomy & Histopathology, University of Health Sciences, Lahore-Pakistan.
Sobia Khalid
Department of Morbid Anatomy & Histopathology, University of Health Sciences, Lahore-Pakistan.
Nadia Naseem
Head, Department of Morbid Anatomy & Histopathology, University of Health Sciences, Lahore-Pakistan.
AH Nagi
Department of Morbid Anatomy & Histopathology, University of Health Sciences, Lahore-Pakistan
Publication History
Received: March 12, 2020
Revised: June 11, 2020
Accepted: June 20, 2020
Published: June 30, 2020
Abstract
Breast cancer is the second most common cancer in the world according to World Health Organization statistics. Among Asian countries, Pakistan has the highest incidence of breast cancer. The normal breast development is interplay between various hormones and transcription factors. Estrogen receptor, progesterone receptor and human epidermal growth factor are being utilized for the targeted therapy of breast cancers. However, there is further need of research to improve the treatment strategies in this regard. Secreted Protein Acidic and Rich in Cysteine (SPARC) is a new biomarker and therapeutic target in breast cancer as well as other tumor types. It’s a matricellular protein whose main function is to mediate interactions between cells and their extracellular surrounding during morphogenesis, tissue remodeling and angiogenesis. Therefore, SPARC enables tumor cells to interact with stromal cells and the extracellular matrix. Regarding breast carcinoma, SPARC has been identified as an important negative regulator of tumor characteristics associated with poor prognosis.
Keywords: Breast cancer, SPARC, Estrogen receptor, Progesterone receptor, Her2neu receptor, Targeted therapy.
Pubmed Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. SPARC in Breast Carcinomas: A Critical Review. BioMedica. 2020; 30 (June 2020): 109-117. doi:10.24911/BioMedica/5-123
Web Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. SPARC in Breast Carcinomas: A Critical Review. https://biomedicapk.com/articles/online_first/123 [Access: May 07, 2024]. doi:10.24911/BioMedica/5-123
AMA (American Medical Association) Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. SPARC in Breast Carcinomas: A Critical Review. BioMedica. 2020; 30 (June 2020): 109-117. doi:10.24911/BioMedica/5-123
Vancouver/ICMJE Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. SPARC in Breast Carcinomas: A Critical Review. BioMedica. (2020), [cited May 07, 2024]; 30 (June 2020): 109-117. doi:10.24911/BioMedica/5-123
Harvard Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi (2020) SPARC in Breast Carcinomas: A Critical Review. BioMedica, 30 (June 2020): 109-117. doi:10.24911/BioMedica/5-123
Chicago Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. "SPARC in Breast Carcinomas: A Critical Review." 30 (2020), 109-117. doi:10.24911/BioMedica/5-123
MLA (The Modern Language Association) Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi. "SPARC in Breast Carcinomas: A Critical Review." 30.June 2020 (2020), 109-117. Print. doi:10.24911/BioMedica/5-123
APA (American Psychological Association) Style
Waqas Arshad Mughal, Sobia Khalid, Nadia Naseem, AH Nagi (2020) SPARC in Breast Carcinomas: A Critical Review. , 30 (June 2020), 109-117. doi:10.24911/BioMedica/5-123